Protagonist Therapeutics (PTGX) Non Operating Income (2016 - 2026)

Protagonist Therapeutics has disclosed Non Operating Income across 10 years of filings, most recently posting $53000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $53000.0, down 35.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2000.0 (down 100.57% YoY), and the FY2025 annual result was $27000.0, down 89.2% from the prior year.
• Non Operating Income came in at $53000.0 for Q1 2026 at Protagonist Therapeutics, up from -$124000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $141000.0 in Q3 2024 to a low of -$195000.0 in Q1 2023.
• The 5-year median for Non Operating Income is $31000.0 (2024), against an average of $2882.4.
• Across the five-year window, Non Operating Income soared 646.15% in 2022 and tumbled 1600.0% in 2023, its largest moves.
• Protagonist Therapeutics' Non Operating Income stood at $71000.0 in 2022, then tumbled by 38.03% to $44000.0 in 2023, then fell by 29.55% to $31000.0 in 2024, then tumbled by 500.0% to -$124000.0 in 2025, then soared by 142.74% to $53000.0 in 2026.
• The last three Non Operating Income figures came in at $53000.0 (Q1 2026), -$124000.0 (Q4 2025), and $33000.0 (Q3 2025), per Business Quant data.